Zobrazeno 1 - 10
of 213
pro vyhledávání: '"G. J. de Jong"'
Autor:
Luis Puig, Antonio Costanzo, Elke M. G. J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2539-2558 (2024)
Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clini
Externí odkaz:
https://doaj.org/article/ab526a4a99574512a77a238ef4a81a03
Autor:
Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert, Elke M. G. J. de Jong
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologi
Externí odkaz:
https://doaj.org/article/ab7d40e11f4f41fcafe65e91de08034d
Autor:
Michelle L. M. Mulder, Tamara W. van Hal, Mark H. Wenink, Hans J. P. M. Koenen, Frank H. J. van den Hoogen, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Johanna E. Vriezekolk
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-22 (2021)
Abstract Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients that are (at risk for) developing PsA is essential to prevent structural damage. We conducted a systematic search of five
Externí odkaz:
https://doaj.org/article/e6fc5ebba49a41f6b2b072fcc29b0aec
Autor:
Arthur Kavanaugh, Kim Papp, Alice B. Gottlieb, Elke M. G. J. de Jong, Soumya D. Chakravarty, Shelly Kafka, Wayne Langholff, Kamyar Farahi, Bhaskar Srivastava, Jose U. Scher
Publikováno v:
BMC Rheumatology, Vol 2, Iss 1, Pp 1-10 (2018)
Abstract Background To evaluate demographics, family history, and previous medication use at enrollment in a subset of psoriasis patients with self-reported psoriatic arthritis (PsA) enrolled in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Externí odkaz:
https://doaj.org/article/4f5c6b72b6e84626be65abf204c5e4a4
Autor:
Michelle L. M. Mulder, Xuehui He, Juul M. P. A. van den Reek, Paulo C. M. Urbano, Charlotte Kaffa, Xinhui Wang, Bram van Cranenbroek, Esther van Rijssen, Frank H. J. van den Hoogen, Irma Joosten, Wynand Alkema, Elke M. G. J. de Jong, Ruben L. Smeets, Mark H. Wenink, Hans J. P. M. Koenen
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 20, p 10990 (2021)
Psoriasis (Pso) is a chronic inflammatory skin disease, and up to 30% of Pso patients develop psoriatic arthritis (PsA), which can lead to irreversible joint damage. Early detection of PsA in Pso patients is crucial for timely treatment but difficult
Externí odkaz:
https://doaj.org/article/8b636d46c1d44143b622a085ca31a173
Autor:
Astrid M. van Huizen, Gayle E. van der Kraaij, Celine I. Busard, Wouter Ouwerkerk, Juul M. P. A. van den Reek, Stef P. Menting, Errol P. Prens, Theo Rispens, Annick de Vries, Elke M. G. J. de Jong, Jo Lambert, Martijn B. A. van Doorn, Phyllis I. Spuls
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. Wiley-Blackwell
Background: Anti-drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non-response. Combination therapy of ADL and methotrexate (MTX) reduces ADA levels an
Autor:
Michelle L M Mulder, Johanna E Vriezekolk, Tamara W van Hal, Lieke M Nieboer, Nathan den Broeder, Elke M G J de Jong, Alfons A den Broeder, Frank H J van den Hoogen, Philip S Helliwell, Mark H Wenink
Publikováno v:
The Lancet. Rheumatology, 4, 4, pp. E252-E261
The Lancet. Rheumatology, 4, E252-E261
The Lancet. Rheumatology, 4, E252-E261
Item does not contain fulltext
Autor:
Inge M. G. J. Bronckers, Elke M. G. J. de Jong, Celia A. J. Michielsens, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Marieke M. B. Seyger
Publikováno v:
JEADV : Journal of the European Academy of Dermatology and Venereology, 37, 7, pp. e894-e897
JEADV : Journal of the European Academy of Dermatology and Venereology, 37, e894-e897
JEADV : Journal of the European Academy of Dermatology and Venereology, 37, e894-e897
Item does not contain fulltext 01 juli 2023
Autor:
L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek
Publikováno v:
Archives of Dermatological Research.
Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore pa
Autor:
Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Milan Tjioe
Publikováno v:
Journal of Dermatological Treatment, 34, 1
Journal of Dermatological Treatment, 34
Journal of Dermatological Treatment, 34
The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited. (1) to estimate the prevalence of SARS-CoV-2 infection in patients with psor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::571a13a3c970bfb57e2c621285f58395